Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06192589 · ClinicalTrials.gov registry record · Phase 1
Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions
A Phase 1 study of Drug Interaction and Drug Induced Liver Injury, sponsored by Food and Drug Administration (FDA).
- Completed
- Registry status
- Phase 1
- Development phase
- 241
- Enrollment target
- 1
- Study location
NCT06192589: Completed Phase 1 study of Drug Interaction and Drug Induced Liver Injury, sponsored by Food and Drug Administration (FDA).
NCT06192589 is a Phase 1 study of Drug Interaction and Drug Induced Liver Injury that has completed, run by Food and Drug Administration (FDA). The registered enrollment target is 241 participants, above the 18-participant average among 3 other Drug Interaction trials with a reported enrollment target (1239% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06192589, a Phase 1 study of Drug Interaction and Drug Induced Liver Injury, has completed, sponsored by Food and Drug Administration (FDA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 241 participants
- Enrollment target
- 1
- Study location
Study Summary
Cannabidiol (CBD) is available as a prescription drug product for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. At labeled doses up to 25 mg/kg/day, an increased risk of liver enzyme elevation and drug-induced liver injury has been observed. However, only limited evaluations of the risk of liver enzyme elevation of daily, lower dose CBD use are available. The potential for liver enzyme elevations with lower CBD doses with unapproved consumer products highlights a need for further research. In addition, CBD has the capacity to inhibit cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases, leading to potential drug-drug interactions with multiple common medications. The clinical significance of many of these interactions is also unclear. Furthermore, nonclinical studies have suggested the potential for CBD to cause reproductive and endocrine effects. As such, additional high-quality clinical pharmacology studies are needed to further characterize CBD's safety profile. The objective of this study is to characterize the effects of daily CBD use at a dose within the range of what consumers are taking as unapproved CBD products on liver enzyme elevations, drug interactions, and endocrine measures.
Primary Outcome
The upper limit of normal (ULN), based on consensus criteria, for the liver transaminase ALT (Alanine transaminase) is defined as 33 U/L for males and 25 U/L for females. An ALT evaluation three times the ULN for males would be 99 U/L and 75 U/L for females.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cannabidiol
- DRUG Morphine
- DRUG Citalopram
Study Locations (1)
Wisconsin
- Spaulding Clinical Research - West Bend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2024-02-08 |
| Est. Completion | 2024-09-06 |
| Phase | Phase 1 |
What the finished NCT06192589 record still lists
NCT06192589 is an interventional study that assigns participants to a tested intervention. The registered 241 participants enrollment target is mid-sized for trials with a published cap, above the 18-participant average among 3 other Drug Interaction trials with a reported enrollment target (1239% higher).
The record links to 3 conditions, with Drug Interaction appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06192589 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06192589 about?
NCT06192589 is a clinical study titled "Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions". Cannabidiol (CBD) is available as a prescription drug product for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. At labeled doses up to 25 mg/kg/day, an increased risk of liver enzyme elevation and drug-induced liver injury has been...
What is the current status of trial NCT06192589?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 241 participants. The study started on 2024-02-08. Estimated completion is 2024-09-06.
What conditions does trial NCT06192589 study?
This clinical trial studies the following conditions: Drug Interaction, Drug Induced Liver Injury, Cannabidiol.
What interventions are being tested in trial NCT06192589?
The interventions under investigation include: Placebo (DRUG), Cannabidiol (DRUG), Morphine (DRUG), Citalopram (DRUG).
Who is sponsoring clinical trial NCT06192589?
This trial is sponsored by Food and Drug Administration (FDA), which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06192589 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug Interaction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01189786 · 241 participants · NA
Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection
- NCT05050383 · 241 participants · NA
DISE: Phenotyping Obstruction Patterns
- NCT05683418 · 241 participants · Phase 1
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
- NCT07213791 · 241 participants · Phase 1
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI